Home › News › Quality / GMP

Novartis' Cosentyx Receives US FDA Approval for Polymyalgia Rheumatica

Novartis' Cosentyx Receives US FDA Approval for Polymyalgia Rheumatica

Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) 150 mg for treating adults with polymyalgia rheumatica (PMR) who have an inadequate response to corticosteroids or cannot tolerate corticosteroid tapering. It is the first and only anti-interleukin-17 (IL-17) biologic approved for this indication.

PMR is an inflammatory disease primarily affecting adults aged 50 years and above, causing pain and stiffness in the shoulders, neck and hips. Corticosteroids remain the standard treatment, but prolonged use can increase the risk of complications, including osteoporosis, cardiovascular disease and diabetes.

The approval is based on results from the Phase 3 REPLENISH trial, in which Cosentyx 150 mg achieved sustained remission in 40.5 percent of patients at Week 52, compared with 20.5 percent in the placebo group, following a 24-week steroid tapering regimen. The trial also evaluated the safety and efficacy of the treatment, with its safety profile remaining consistent with the established profile of Cosentyx.

Cosentyx is a fully human biologic that selectively inhibits interleukin-17A, a cytokine involved in inflammation. The medicine is already approved for several immune-mediated conditions, including plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

According to Novartis, the latest approval expands Cosentyx's US indications and provides an additional treatment option for patients with PMR who have limited alternatives to long-term corticosteroid therapy. The company has also submitted the clinical data for regulatory review in Japan and other countries.

More news about: quality / gmp | Published by News Bureau | November - 18 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members